Immunological combination treatment holds the key to improving survival in pancreatic cancer
| Autor: | Harpreet Wasan, Long R. Jiao, Anguraj Sadanandam, Mikael H. Sodergren, V. P. Balachandran, Nagy A. Habib, Nagina Mangal |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Review – Clinical Oncology medicine.medical_treatment Immune system Stroma Pancreatic cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Cancer Chemotherapy Hematology Pancreatic business.industry General Medicine Immunotherapy medicine.disease Combined Modality Therapy Pancreatic Neoplasms Clinical trial Vaccination Combination business Carcinoma Pancreatic Ductal |
| Zdroj: | Journal of Cancer Research and Clinical Oncology |
| ISSN: | 1432-1335 0171-5216 |
| Popis: | Advances in surgery, peri-operative care and systemic chemotherapy have not significantly improved the prognosis of pancreatic cancer for several decades. Early clinical trials of immunotherapy have yielded disappointing results proposing other means by which the tumour microenvironment serves to decrease the immune response. Additionally, the emergence of various subtypes of pancreatic cancer has emerged as a factor for treatment responses with immunogenic subtypes carrying a better prognosis. Herein we discuss the reasons for the poor response to checkpoint inhibitors and outline a rationale why combination treatments are likely to be most effective. We review the therapies which could provide optimal synergistic effects to immunotherapy including chemotherapy, agents targeting the stroma, co-stimulatory molecules, vaccinations and methods of immunogenic tumour priming including radiofrequency ablation. Finally, we discuss reasons why peri-operative and in particular neoadjuvant combination treatments are likely to be most effective and should be considered for early clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink